In NSCLC, the co-occurrence of KRAS and Serine/Threonine Kinase 11 (STK11) mutations is associated with the diverse phenotypic and heterogeneous oncogenic subtypes in the so-called “KRAS KL” NSCLC subgroup [11]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.